title: [18F]Fluorodeoxyglucose PET in Thoracic Malignancies.
abstract: [(18)F]Fluorodeoxyglucose (FDG) PET is a robust quantitative molecular imaging technique that complements available structural imaging techniques for the detection and characterization of malignancy. This article provides an overview of the utility and applications of FDG-PET for the evaluation of patients with thoracic malignancy.
authors.affiliation: Department of Nuclear Medicine, Odense University Hospital, Sdr. Boulevard 29, Odense 5000, Denmark.
authors.forename: Mie Holm
authors.initials: MH
authors.lastname: Vilstrup
authors.affiliation: Department of Radiology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA. Electronic address: Drew.Torigian@uphs.upenn.edu.
authors.forename: Drew A
authors.initials: DA
authors.lastname: Torigian
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging / Q000473:pathology / Q000628:therapy; D004938:Esophageal Neoplasms / Q000000981:diagnostic imaging; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology / Q000628:therapy; D008654:Mesothelioma / Q000000981:diagnostic imaging; D009367:Neoplasm Staging; D010997:Pleural Neoplasms / Q000000981:diagnostic imaging; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D013899:Thoracic Neoplasms / Q000000981:diagnostic imaging*; D013953:Thymus Neoplasms / Q000000981:diagnostic imaging
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
keywords: Esophageal cancer; Fluorodeoxyglucose (FDG); Lung cancer; Malignant pleural mesothelioma; Thoracic malignancy; Thymic tumors